ROIV250117P9000
- 0.65
- 0.000.00%
Roivant Sciences Newsroom
Roivant Sciences Insider Sold Shares Worth $4,971,637, According to a Recent SEC Filing
Roivant Sciences(ROIV.US) Officer Sells US$4.97 Million in Common Stock
$Roivant Sciences(ROIV.US)$ Officer Sukhatme Mayukh sold 412.58K shares of common stock on Dec 18, 2024 at an average price of $12.05 for a total value of $4.97 million.Source: Announcement What is
Five Reasons Why UBS Is Overweight the UK
Roivant Sciences (ROIV) Receives a Buy From Leerink Partners
Optimistic Outlook on Roivant Sciences Despite Namilumab Setback
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Roivant will cease the development of a lung disease drug due to the mid-term trial not meeting its goals.
Globe Union, December 3 | Roivant will cease the development of a drug for treating a rare lung disease because it did not demonstrate therapeutic effects on patients in a mid-stage trial. Kinevant Sciences, a subsidiary of the company, announced on Tuesday that its once-monthly injectable drug nanobody failed to meet primary and secondary endpoints in a study that evaluated 107 patients with chronic active pulmonary sarcoidosis over approximately six months. This disease causes inflammatory cell masses to form in the lungs and other organs, leading to tissue damage and organ dysfunction. According to the usa Lung Association (
Roivant Sciences Ends Namilumab Study Due to Inefficacy
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
Express News | Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis
Express News | Roivant Announces Topline Results From Phase 2 Resolve-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Kinevant Sciences Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Roivant Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
Vivek Ramaswamy's Marching Orders: Cut Trillions for Trump -- WSJ